FI3423087T3 - Syövän vastainen yhdistelmähoito - Google Patents

Syövän vastainen yhdistelmähoito Download PDF

Info

Publication number
FI3423087T3
FI3423087T3 FIEP17709038.8T FI17709038T FI3423087T3 FI 3423087 T3 FI3423087 T3 FI 3423087T3 FI 17709038 T FI17709038 T FI 17709038T FI 3423087 T3 FI3423087 T3 FI 3423087T3
Authority
FI
Finland
Prior art keywords
adjuvant
immunotherapeutic composition
use according
montanide isa
cancer treatment
Prior art date
Application number
FIEP17709038.8T
Other languages
English (en)
Finnish (fi)
Inventor
Mads Andersen
Original Assignee
Io Biotech Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1603805.1A external-priority patent/GB201603805D0/en
Priority claimed from GBGB1610018.2A external-priority patent/GB201610018D0/en
Application filed by Io Biotech Aps filed Critical Io Biotech Aps
Application granted granted Critical
Publication of FI3423087T3 publication Critical patent/FI3423087T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FIEP17709038.8T 2016-03-04 2017-03-03 Syövän vastainen yhdistelmähoito FI3423087T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1603805.1A GB201603805D0 (en) 2016-03-04 2016-03-04 Combination
GBGB1610018.2A GB201610018D0 (en) 2016-06-08 2016-06-08 Combination
PCT/EP2017/055093 WO2017149150A1 (en) 2016-03-04 2017-03-03 Combination therapy against cancer

Publications (1)

Publication Number Publication Date
FI3423087T3 true FI3423087T3 (fi) 2023-12-15

Family

ID=58231605

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP17709038.8T FI3423087T3 (fi) 2016-03-04 2017-03-03 Syövän vastainen yhdistelmähoito

Country Status (13)

Country Link
US (2) US20190343940A1 (enExample)
EP (2) EP3423087B1 (enExample)
JP (3) JP2019507180A (enExample)
DK (1) DK3423087T3 (enExample)
ES (1) ES2965009T3 (enExample)
FI (1) FI3423087T3 (enExample)
HR (1) HRP20240052T1 (enExample)
HU (1) HUE064857T2 (enExample)
LT (1) LT3423087T (enExample)
PL (1) PL3423087T3 (enExample)
PT (1) PT3423087T (enExample)
SI (1) SI3423087T1 (enExample)
WO (1) WO2017149150A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
CA3001131A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
HUE064857T2 (hu) * 2016-03-04 2024-04-28 Io Biotech Aps Kombinációs terápia a rák ellen
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
CN110546509A (zh) 2017-04-28 2019-12-06 戊瑞治疗有限公司 用cd80细胞外结构域多肽进行治疗的方法
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
WO2019102265A1 (en) * 2017-11-23 2019-05-31 Theraphage Inc. Peptide displaying bacteriophage nanoparticles and related compositions and methods
EP3713645A1 (en) * 2017-11-24 2020-09-30 IO Biotech APS Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc)
WO2019165077A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
AU2019361923B2 (en) 2018-10-15 2026-07-09 Five Prime Therapeutics, Inc. Combination therapy for cancer
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
AU2020224137B2 (en) 2019-02-22 2026-01-08 Five Prime Therapeutics, Inc. CD80 extracellular domain-Fc fusion proteins for treating PD-L1 negative tumors
MX2021013272A (es) 2019-05-03 2021-11-17 Five Prime Therapeutics Inc Formulaciones farmaceuticas que contienen proteinas de fusion fc de dominio extracelular de cd80.
KR102653960B1 (ko) * 2020-07-23 2024-04-03 의료법인 성광의료재단 암 치료를 위한 면역체크포인트 억제제의 병용 요법
BR112023017582A2 (pt) 2021-03-05 2023-12-05 Univ Basel Composições para o tratamento de doenças ou condições associadas ao ebv
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
GB202103673D0 (en) * 2021-03-17 2021-04-28 Io Biotech Aps Combination therapy for cancer
CN117642432A (zh) * 2021-05-17 2024-03-01 威斯康星校友研究基金会 用于诱导免疫耐受的合成蛋白
EP4479085A1 (en) * 2022-02-18 2024-12-25 ModernaTX, Inc. Mrnas encoding checkpoint cancer vaccines and uses thereof
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy
WO2026008017A1 (en) * 2024-07-03 2026-01-08 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US20100055111A1 (en) * 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
DK2280721T3 (da) * 2008-04-17 2018-01-29 Io Biotech Aps Indoleamin-2, 3-dioxygenasebaseret immunterapi
ES2918580T3 (es) * 2011-10-17 2022-07-19 Io Biotech Aps Inmunoterapia basada en PD-L1
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
PH12020550847A1 (en) * 2014-02-04 2022-05-11 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
ES2715018T3 (es) * 2014-05-30 2019-05-31 Ventana Med Syst Inc Ensayo múltiple para puntuar mejor los tejidos tumorales teñidos para PD-L1
HUE064857T2 (hu) * 2016-03-04 2024-04-28 Io Biotech Aps Kombinációs terápia a rák ellen

Also Published As

Publication number Publication date
LT3423087T (lt) 2024-01-25
US20190343940A1 (en) 2019-11-14
EP3423087A1 (en) 2019-01-09
PT3423087T (pt) 2023-12-28
ES2965009T3 (es) 2024-04-10
HRP20240052T1 (hr) 2024-03-29
PL3423087T3 (pl) 2024-05-20
WO2017149150A1 (en) 2017-09-08
JP2024045180A (ja) 2024-04-02
JP7417645B2 (ja) 2024-01-18
EP3423087B1 (en) 2023-11-15
HUE064857T2 (hu) 2024-04-28
EP4316517A2 (en) 2024-02-07
JP2019507180A (ja) 2019-03-14
US20220257741A1 (en) 2022-08-18
DK3423087T3 (da) 2023-12-18
SI3423087T1 (sl) 2024-03-29
EP4316517A3 (en) 2024-05-29
JP7785817B2 (ja) 2025-12-15
JP2022068348A (ja) 2022-05-09

Similar Documents

Publication Publication Date Title
HRP20240052T1 (hr) Kombinirana terapija protiv raka
WO2021226436A8 (en) Optimized nucleotide sequences encoding sars-cov-2 antigens
WO2011071574A3 (en) Monoclonal antibodies against glycoprotein of ebola sudan boniface virus
WO2018115527A3 (en) Mers coronavirus vaccine
EA201890006A1 (ru) Применение экзосом для лечения болезни
WO2019226514A3 (en) Molecular gene signatures and methods of using same
NZ737796A (en) Anti-tau antibodies and methods of use
EA201892803A1 (ru) Противоопухолевая терапия
EP4233898A3 (en) Influenza mrna vaccines
AR106752A1 (es) Proteínas de unión a pd1 / ctla4
PH12022552125A1 (en) Stabilized soluble pre-fusion rsv f proteins
WO2015143123A3 (en) Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
PH12019550069A1 (en) Nucleoside phosphate compound and preparation method and use thereof
PH12018502332A1 (en) Stabilized pre-fusion rsv f proteins
MX2019000725A (es) Composiciones de vacuna para tratamiento de virus zika.
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
WO2019066435A3 (ko) Bcma에 높은 친화도를 가지는 항-bcma 항체 및 이를 포함하는 암 치료용 약학적 조성물
EP4368207A3 (en) Ovarian cancer vaccines
HK1252343A1 (zh) 用於治疗病毒感染的组合物和方法
EA201391199A1 (ru) Композиции из hyr1-производных и способы лечения ими
WO2013016278A3 (en) Modulators of antiviral signaling pathways and therapeutic uses thereof
UA102274C2 (ru) Эпитопный пептид rab6kifl/kif20a и вакцины, которые его содержат
WO2017158184A3 (de) Antivirale immuntherapie durch membranrezeptorligation
IL274363B2 (en) Use of specific sirna against protein s for the treatment of hemophilia
MX2021015026A (es) Peptido derivado de urlc10 y vacuna que lo contiene.